Related Experiment Video
Updated: Sep 27, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
[Mid-term prognostic value of plasma heavy-chain myosin in thrombolysed myocardial infarction]
K Bendjelid1, P Messner, J M Stordeur
1Service de Cardiologie, Hôpital Arnaud De Villeneuve, CHU de Montpellier, 34295 Montpellier.
Insights
An unusual plasma myosin release pattern after myocardial infarction predicts medium-term heart failure and coronary instability. This simple assay identifies high-risk patients early.
Area of Science:
- Cardiology
- Biomarker Discovery
- Myocardial Infarction Research
Context:
- Myocardial infarction (MI) management requires accurate prognostic tools.
- Plasma myosin assays offer a novel method for assessing infarction extent during the acute phase.
- Prognostic value of plasma myosin release kinetics remains understudied compared to serum assays.
Purpose:
- To evaluate the prognostic value of plasma myosin heavy chain assay kinetics in predicting medium-term outcomes after acute myocardial infarction.
- To compare the predictive power of plasma myosin assay with traditional methods for assessing infarction extent.
- To identify patients at high risk for heart failure and coronary insufficiency post-MI.
Summary:
- A study followed 40 patients for two years post-MI, correlating initial plasma myosin assay results with clinical outcomes.
- An unusual (complex) plasma myosin release kinetic was found to predict medium-term heart failure (p=0.04) and coronary insufficiency (p=0.02).
- Five assays over 10 days can identify high-risk patients with complex release kinetics and an area under the curve > 10.470 µL U/L (p=0.043).
Impact:
- This research highlights a simple, accessible method for early identification of high-risk MI patients.
- The findings suggest that plasma myosin kinetics can guide intensified monitoring and treatment strategies.
- Early risk stratification using plasma myosin assays may improve patient outcomes and reduce healthcare costs.
Abstract:
Plasma myosin heavy chain assay, which can be easily performed during the acute phase of myocardial infarction, is a recent method allowing quantitative assessment of the extent of infarction. However, to our knowledge, its prognostic value has not been studied in contrast with serum myosin light chain assay. We monitored the state of health of 40 patients (including 37 men with a mean age of 56 years) for two years after a first myocardial infarction, thrombolized during the acute phase. Their survival (mortality) and the development of "cardiac events" (MI, angina, sudden death, etc.) were evaluated at 2 years. The results observed at 2 years were correlated with the initial plasma myosin assay results and other direct and indirect methods of assessment of the extent of infarction, performed during the acute phase of myocardial infarction (cardiac enzymes, contrast angiography). The main result of this study is the demonstration that an unusual plasma myosin release kinetic (complex appearance) is predictive for the medium-term development of heart failure (p = 0.04) and/or destabilization of coronary insufficiency (p = 0.02). These results need to be emphasized, as with only 5 serum myosin assays performed over a 10-day period, it seems possible to identify a group of patients at high risk of medium-term complications, who possess a complex release kinetic during the acute phase of myocardial infarction and a value for area under the curve greater than 10.470 microliters U/L (cut-off value, p = 0.043).
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy

